Pharmaceutical composition comprising of ubidecarenone (coenzyme Q10) and HMO CoA reductase inhibitor preferably atorvastatin formulated as film coated tablet dosage form useful for the treatment of elevated blood lipid level-related diseases and conditions associated with coenzyme Q10 deficiency and process for preparation thereof, are disclosed herein.